Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 698 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas Harbouring NF2 or CDK Pathway Alterations MOST POPULAR FDA Approves Lenvatinib Plus Pembrolizumab for Advanced Renal Cell Carcinoma August 12, 2021 ctDNA Sequencing Reliably Detects KIT/PDGFRA Mutations and Correlates with Outcomes in... May 23, 2023 PET Positivity After Two Cycles of ABVD Is Associated with a... November 22, 2023 Cancer Does Not Affect All People Equally: An Expert Q&A on... June 30, 2020 Load more HOT NEWS FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT... The Taylor Family Foundation gives £2.1m to support head and neck... If You Let It, Nursing Will Change Your Life Using Aspirin to Prevent Breast Cancer Recurrence and Targeted Therapy for...
